胰岛素样生长因子I受体参与甲状腺相关眼病的争议
本文综述甲状腺相关眼病(TAO)发病机制中胰岛素样生长因子I受体(IGF-IR)的作用。TSHR与IGF-IR在眶成纤维细胞及CD34+纤维细胞上过表达并形成信号复合物,介导透明质酸生成与细胞因子表达;针对IGF-IR的选择性全身抑制已发展为TAO的靶向治疗,但认识仍存在重要空白,现有治疗亦有局限。
要点
- TSHR与IGF-IR在GD-OF及CD34+纤维细胞上过表达并形成信号复合物
- 该复合物介导对致病性IgG的细胞反应,促进透明质酸与细胞因子产生
- 选择性全身抑制IGF-IR已形成TAO的靶向治疗,但现有疗法仍有局限
核心结论
- 近数十年对TAO发病机制的认识显著增加,其中包括确认IGF-IR是支撑该疾病的关键组分,并由此直接促成了有效靶向治疗的开发。
- 认识上仍存在重要空白,当前治疗存在局限,尽管取得上述进展,仍有相当多工作有待完成。
研究设计与样本
- 本文为综述,检索PubMed数据库,覆盖自最早收录时期起的文献。
- 主要检索关键词包括thyroid-associated ophthalmopathy、Graves' orbitopathy、TED、orbit、TSH receptor、IGF-I receptor及autoimmune thyroid disease,并采用众多其他检索词进行二次检索。
主要发现
- GD-OF被广泛表征为对TAO发病机制中的免疫因素和关键效应物特别敏感。
- TSHR与IGF-IR均在GD-OF和CD34+纤维细胞上过表达并形成信号复合物,经该复合物激活后产生大量透明质酸并表达多种细胞因子。
- 该复合物介导细胞对TAO中致病性IgG的反应;CD34+纤维细胞和CD34+ OF还表达相对较高水平的多种甲状腺自身抗原。
- 将IGF-IR识别为受体复合物的关键组分及其与TSHR信号活动的交织,促成了TAO的靶向药物治疗,即选择性全身抑制IGF-IR。
临床怎么用
- 作者指出,将IGF-IR识别为受体复合物的关键组分并明确其与TSHR信号的交织,已直接促成针对TAO的靶向药物治疗,该治疗涉及选择性全身抑制IGF-IR。
局限性
- 作者指出,认识上仍存在重要空白,当前治疗存在局限,尽管取得上述进展,仍有相当多工作有待完成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Thyroid-associated ophthalmopathy (TAO, aka thyroid eye disease [TED], Graves' orbitopathy) remains poorly understood and inadequately treated since its initial description. It is disfiguring, can threaten vision, and represents an autoimmune process closely associated with thyroid disease. Unambiguous connections linking TAO to the glandular maladies of Graves' disease (GD) remain incompletely clarified. Detecting the thyrotropin receptor (TSHR) in periocular tissues suggests that this cell-surface protein represents a shared autoantigen with the thyroid gland, but we now know that its expression is ubiquitous. Most patients with TAO have relatively high circulating levels of activating anti-TSHR autoantibodies. Emerging more recently is the importance of insulin-like growth factor I receptor (IGF-IR) in the pathogenesis of TAO. The TSHR/IGF-IR signaling complex apparently drives circulating fibrocytes and the unique phenotypes of fibroblasts inhabiting the TAO orbit (GD-OF). Methods: The PubMed database was scanned for articles dating back to the earliest time periods covered. Keywords used for primary searches included thyroid-associated ophthalmopathy, Graves' orbitopathy, TED, orbit, TSH receptor, IGF-I receptor, and autoimmune thyroid disease. Secondary searches used numerous other search terms. Results: GD-OF have been characterized extensively as being particularly responsive to the immunological factors and key effectors in TAO pathogenesis. Both TSHR and IGF-IR are overexpressed by GD-OF and CD34+ fibrocytes and form a signaling complex. They are activated through this TSHR/IGF-IR complex to produce large amounts of hyaluronan and express multiple cytokines. This complex mediates cellular responses to pathogenic IgGs in TAO. CD34+ fibrocytes and CD34+ OF also express relatively high levels of multiple thyroid autoantigens. Identifying IGF-IR as a key component of a receptor complex and its intertwining signaling activities with those of TSHR has led to a targeted medical therapy for TAO. This therapy involves the selective systemic inhibition of IGF-IR. Conclusions: Much has been learned over the preceding decades about the pathogenesis of TAO. Among these is the identification of IGF-IR as a pivotal component underpinning the disease. This has led directly to development of an effective targeted therapy. Important gaps in our understanding persist, and current therapies have limitations. Thus, despite these advancements, considerably more remains to be achieved.
引用
- Smith TJ. Controversies Surrounding IGF-I Receptor Involvement in Thyroid-Associated Ophthalmopathy. Thyroid. 2025. PMID: 39909461. doi:10.1089/thy.2024.0606
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。